Wide Ranks

ARGX

argenx SE

614.59

Top Statistics
Market Cap 36 B Forward PE 72.77 Revenue Growth 73.30 %
Current Ratio 0.00 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -2.11 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -224.42 Enterprise / Revenue 17.65 Price To Sales Trailing12 Months 19.25
Profitability
Profit Margins -2.11 % Operating Margins 2.75 %
Balance Sheet
Total Cash 3 B Total Cash Per Share 51.88 Total Debt 33 M
Total Debt To Equity 0.7970 Current Ratio 0.00 Book Value Per Share 71.28
All Measures
Short Ratio 751.00 % Message Board Id finmb_62120637 Shares Short Prior Month 1 M
City Amsterdam Uuid 96295c13-e973-32ba-ba5e-28b94bffe0bd Previous Close 607.16
First Trade Date Epoch Utc 1 B Book Value 71.28 Beta 0.2670
Total Debt 33 M Volume 347664 Price To Book 8.62
Fifty Two Week Low 327.73 Total Cash Per Share 51.88 Total Revenue 1 B
Shares Short Previous Month Date 1 B Target Median Price 624.25 Max Age 86400
Recommendation Mean 1.48 Sand P52 Week Change 0.3133 Operating Margins 2.75 %
Target Mean Price 627.23 Net Income To Common -40293000 Short Percent Of Float 0.0347
Implied Shares Outstanding 60 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 411390 Average Volume10days 411390 Total Cash 3 B
Next Fiscal Year End 1 B Revenue Per Share 1.28 Held Percent Insiders 0.0000
Ebitda Margins -7.86 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 607.16 Target Low Price 490.84
Gmt Off Set Milliseconds -18000000 Fifty Day Average 562.42 Open 615.61
Dividend Yield 0.00 % Time Zone Short Name EST Trailing Eps -0.8000
Day Low 609.07 Address1 Laarderhoogtweg 25 Shares Outstanding 59 M
Price Hint 2 Target High Price 727.19 Website https://www.argenx.com
52 Week Change 0.3639 Average Volume 279701 Forward Eps 9.69
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Is_sp_500 False
Regular Market Day High 620.28 Profit Margins -2.11 % Debt To Equity 0.7970
Fifty Two Week High 620.28 Day High 620.28 Shares Short 2 M
Regular Market Open 615.61 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 17.65 Revenue Growth 73.30 % Shares Percent Shares Out 0.0347
Currency USD Time Zone Full Name America/New_York Market Cap 36 B
Is_nasdaq_100 False Zip 1101EB Quote Type EQUITY
Industry Biotechnology Long Name argenx SE Regular Market Day Low 609.07
Held Percent Institutions 0.5959 Current Price 614.59 Enterprise To Ebitda -224.42
Financial Currency USD Current Ratio 0.00 Gross Margins 37.83 %
Industry Disp Biotechnology Number Of Analyst Opinions 23 Country Netherlands
Float Shares 59 M Two Hundred Day Average 462.02 Enterprise Value 33 B
Price To Sales Trailing12 Months 19.25 Forward PE 72.77 Regular Market Volume 347664
Ebitda -150084496 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China.

Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115.

It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB.

The company has strategic partnership with AbbVie S.

À.

R.

L.

, Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co.

Ltd, Université Catholique de Louvain, Sopartec S.

A.

, NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.

V.

, VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH.

It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services.

argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.